Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Cantor Fitzgerald from $185.00 to $198.00. They now have an "overweight" rating o

Low REPORT

4/20

08:45 am

jazz

Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Stifel Nicolaus from $195.00 to $202.00. They now have a "buy" rating on the stoc

Low REPORT

4/20

07:45 am

jazz

Jazz Pharmaceuticals Presents Phase 3 Study Results of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia at 2021 American Academy of Neurology Annual Meeting

Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Stifel Nicolaus from $195.00 to $202.00. They now have a "buy" rating on the stoc

Low REPORT

4/12

07:45 am

jazz

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its price target raised by analysts at Morgan Stanley from $162.00 to $176.00. They now have an "equal weight" rating on

Low REPORT

3/30

06:15 pm

jazz

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was downgraded by analysts at TheStreet from a "b" rating to a "c+" rating.

Medium REPORT

3/22

04:05 pm

jazz

Jazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley Forum

The Year Of Cannabis Industry Consolidation [Forbes]

Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic Hypersomnia

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) had its "outperform" rating re-affirmed by analysts at SVB Leerink LLC.

Low REPORT

3/17

10:21 am

jazz

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was upgraded by analysts at Zacks Investment Research from a "strong sell" rating to a "hold" rating. They now have a $181.

Low REPORT

3/3

06:01 pm

jazz

Jazz Pharmaceuticals (JAZZ) Investor Presentation - Slideshow [Seeking Alpha]

Low REPORT

Live Event:

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.